Bristol-Myers Squibb Co(BMY)stock report

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 3.01 393.44% 30.87%
2019.3.31 1.05 15.38% -65.12%
2019.6.30 1.92 68.42% 82.86%
2019.9.30 2.75 19.57% 43.23%


Date Sales % last year % last quarter
2018.12.31 22561M 8.59% 36.01%
2019.3.31 5920M 14.00% -73.76%
2019.6.30 12193M 11.89% 105.96%
2019.9.30 18200M 9.72% 49.27%


Insider Transactions:

Institution Ownership:

Total institutions: 2219,no change
Shares hold: 1914000k shares. Increase 5k
shares% hold: 117.45%,decreased by 0.02%

Analyst Ratings:

Leave a Reply